Benjamin D Greenbaum, PhD Email Benjamin Greenbaum
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSOCIATE PROFESSOR | Pathology
- ASSOCIATE PROFESSOR | Oncological Sciences
I am a theoretical physicist working in quantitative biology at the intersection of cancer research, immunology, evolutionary theory, and virology. I currently collaborate with the Icahn Institute for Data Science and Genomic Technology. Our lab uses tools from physics, mathematics and computer science to better understand how self versus non-self discrimination occurs and the role such discrimination plays in the evolution of tumors and viruses. Previously, we showed how single-stranded RNA viruses evolve to mimic the genomic environment of their hosts. We found that the original 1918 influenza lineage altered its genome to mimic nucleotide motif composition features of the human genome, likely to evade targeting of those motifs by innate immune receptors, and found that such host genome mimicry is a generic feature of many viruses.
The significance of the immune mechanisms in cancer has recently become fully appreciated. As a result we working on several topics related to immunotherapy and cancer immunology. We are studying the role of the immune system in several cancers, particularly the interaction of host tumoral RNA with the innate immune system, the role of neoantigens in the evolution of tumors both generally and in response to therapy, and the role of endogenous and exogenous viruses in cancer. In addition to shedding light on these scientific issues, we are working to translate our work into clinically impactful results in cancer immunotherapy. At the same time we continue to develop theoretical approaches to a variety of fundamental problems in host and viral genome evolution.
For publications see:
For inquires about positions please contact Estefani Flores: firstname.lastname@example.org
PhD, Columbia University
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Greenbaum did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.